Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Abstract Background Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen th...

Full description

Bibliographic Details
Main Authors: Victoria M. Kim, Alex B. Blair, Peter Lauer, Kelly Foley, Xu Che, Kevin Soares, Tao Xia, Stephen T. Muth, Jennifer Kleponis, Todd D. Armstrong, Christopher L. Wolfgang, Elizabeth M. Jaffee, Dirk Brockstedt, Lei Zheng
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Pancreatic cancer
Immunotherapy
Annexin A2
Anti-PD-1 antibody, interferon-gamma, CD8 T cells
Online Access:http://link.springer.com/article/10.1186/s40425-019-0601-5

Internet

http://link.springer.com/article/10.1186/s40425-019-0601-5

Similar Items